Top news of the week: 14.07.2020.
Biotechnology, Malaria, Immunohistochemistry, Allergy, Capital punishment, Dot-com bubble
Startups
This startup might finally cure sickle cell disease—After a century of racist neglect
https://t.co/rqRSm9SQly By @katiedjennings https://t.co/IqUtmfpbH7
OpenThis Startup Might Finally Cure Sickle Cell Disease—After A Century Of Racist Neglect
The painful blood disorder, which mostly affects Black people, is just one of thousands of rare diseases that could be cured by Beam Therapeutics' revolutionary gene editing technology.
Sanofi pays $150M upfront, $2B in biobucks to tap protein degrader biotech Kymera https://t.co/G8Kc3YxVzm https://t.co/Fxuj3yOuA0
OpenSanofi pays $150M upfront, $2B in biobucks to tap protein degrader biotech Kymera
While Sanofi is looking to move more of its R&D in-house, there is still room for deals, and today it’s penned a big one with Fierce 15 winner Kymera Therapeutics.
RT @IAmBiotech: #COVID19 “has driven the public eye onto what the biotech industry does, which is change the dynamic of a disease,” BIO Chairman and @OvidRx CEO @jmaxlevin said in @USATODAY. https://t.co/BJZfggYd3v https://t.co/pBUHSPsl5Z
OpenCould a coronavirus vaccine rehab the pharmaceutical industry's reputation despite drug price increases?
After years of criticism for price increases, the drug industry hopes to go from villain to hero with a vaccine to end the COVID-19 pandemic.
The #XceleratingLS #XconSD special report recaps event highlights such as innovation and the maturing ecosystem, what it takes for commercialization, and the investment paradigm shift:
https://t.co/uL9SHmkhfC https://t.co/4vy4FBspWc
OpenLearn what's fueling San Diego's biotech investment and partnership opportunities by downloading our special report packaging the highlights from our recent Xcelerating Life Sciences San Diego: Biomedical Breakthroughs in Precision Medicine & Genomics event.
Learn what's fueling San Diego's biotech investment and partnership opportunities with highlights from the Xcelerating Life Sciences San Diego event.
A biotech investor reportedly made $255 million in just 4 weeks on Novavax's 120% surge https://t.co/7ICjcSufz7
OpenA biotech investor reportedly made $255 million in just 4 weeks on Novavax's 120% surge (NVAX)
RA Capital Management, a small biotech investment firm, has made $255 million in paper profits in less than four weeks from a bet on Novavax, Th...
Forbion has followed fellow European VCs Medicxi and Sofinnova Partners in expanding beyond early-stage investing. https://t.co/w5QWoT85cr
OpenForbion moves into late-stage investing with $210M fund
Forbion has expanded into late-stage biotech investing by holding the first close of a planned €250 million ($284 million) fund. The growth fund, which received money from Eil Lilly, will ...
VelosBio Inc., which just raised $137 million in Series B financing, is led by Dave Johnson, who previously led biotech startup Acerta Pharma to a merger with AstraZeneca
https://t.co/gZkM1L9e6A
OpenVelosBio Raises $137 Million Series B Round for Cancer Drug Development
VelosBio Chief Executive David Johnson previously led venture-backed Acerta Pharma BV, a Netherlands–based company with U.S. headquarters in California. U.K.-based drugmaker AstraZeneca ...
Harbour BioMed nabs meaty C round as cancer, COVID-19 work draws investors https://t.co/WlT1xLRS1Y https://t.co/rJLe0GoA1a
OpenHarbour BioMed nabs meaty C round as cancer, COVID-19 work draws investors
Just a few months after a series B-plus worth $75 million, U.S.-China biotech Harbour BioMed has nabbed a major $102.8 million series C, with an IPO surely not far behind.